Zombie Biotech Bite Lilly’s Flab Fight Flops
This week’s ‘The Readout LOUD’ brings us the sad, slow death of a zombie biotech, proving you can’t just stitch dead companies back to life. Meanwhile, Lilly’s obesity drug results are as underwhelming as a flat soda—described simply as ‘disappointing obesity readout.’ If we were looking for a plot twist, we’d better sit down: pharma’s horror story continues with a whimper rather than a bang.
Share the Story
When zombie biotechs stumble and Lilly’s obesity hopes deflate, it’s official: pharma’s more horror story than thriller right now.
Nothing like a biotech graveyard plus disappointment in obesity trials to remind us life and science both love an ironic twist.
If your biotech’s a zombie and your obesity study flops, congrats—you’re the pharmaceutical equivalent of a microwave dinner no one really wanted.
Source: Statnews | Published: 8/7/2025 | Author: Adam Feuerstein, Elaine Chen, and Allison DeAngelis
More Articles in Health
Sam Altman’s Hospital Stay: AI Genius Vs. Semaglutide Junk Food
TrumpRX: Medicare’s New Weight Loss Coke—Now in Pill Form!
90-Year-Old Powerlifters Crush Age, Bones, and Expectations
Forty-Something Brits Take on Identical Triplets: Sleep, Who Needs It?
Pickleball Achilles: From Court Pop to Star-Powered Sobfest
